Serum antimüllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction
Received 23 July 2009; received in revised form 23 November 2009; accepted 1 December 2009. published online 05 February 2010. Corrected Proof
Objective
To determine the possible relationship between serum antimüllerian hormone (AMH) concentrations on day 3 and controlled ovarian stimulation and reproductive outcomes in women with polycystic ovary syndrome.
Design
Prospective, clinical trial.
Setting
University hospital.
Patient(s)
Sixty women with PCOS.
Intervention(s)
Serum concentrations of AMH measured on cycle day 3.
The CPR, IR, and FR were markedly different among the day-3 serum AMH groups (low, moderate, and high AMH groups). The CPR were 33.3, 46.1, and 60.0, respectively, in the low, moderate, and high serum AMH groups on day 3. The embryo IR were 18.6, 26.7, and 36.3, respectively. The FR were 54, 68, and 79, respectively. An AMH level ≥3.01 ng/mL was shown to predict FR with a sensitivity of 86.4% and specificity of 75%. An AMH level ≥3.2 ng/mL was shown to predict IR and CPR with sensitivity and specificity of 72.1% and 72.7%, and 75.6% and 77.3%, respectively.
Conclusion(s)
On day 3 of the in vitro fertilization stimulation cycle, serum concentrations of AMH can be used as a marker for ovarian response as well as reproductive outcome in assisted reproductive cycles of PCOS patients.
aDepartment of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey
bDepartment of Obstetrics and Gynecology, Faculty of Medicine, Ankara University, Ankara, Turkey
Reprint requests: Cemil Kaya, University Hospital, Department of Obstetrics and Gynecology, Ufuk University, Balgat, 312 Ankara, Turkey (FAX: + 90-312-2851158).
C.K. has nothing to disclose. R.P. has nothing to disclose. H.S. has nothing to disclose.
ABSTRACT